- Price
Supplier Type
- Manufacturer
- Trader
- contract manufacturer
- Reagent
- custom synthesis
Supplier Region
- Hyderabad(52)
- Gujarat(90)
- Telangana(3)
- Mumbai(166)
- Kolkata(8)
- Maharashtra(82)
- Kerala(1)
- Ahmedabad(45)
- Beijing(8)
- Karnataka(13)
- West Bengal(1)
- Delhi(33)
- Vadodara(28)
- Andhra Pradesh(7)
- Uttar Pradesh(19)
- Tamil Nadu(7)
- Mallapur(2)
- New Delhi(12)
- Pune(13)
- Haryana(9)
- Rajasthan(1)
- Madhya Pradesh(6)
- Kerela(1)
- Himachal Pradesh(1)
- Bangalore(1)
- Nagpur(2)
- Punjab(3)
- GOA(1)
Purity
- yes
- Purity By Gc Nlt 98%
- powder
- Paste 70%
- NMR
- NLT 98 % NMT 102%
- NLT 95%
- Min. 98 %
- Min. 97.0%
- Min. 97.0 %
- Min. 80%
- Min 99%
- MIN .98.5%
- GUARANTED AS PER SPECIFIC GRADE STANDARD
- Greater than 99%
- Cytidine 5'-Monophosphate Disodium Salt (C9H14N3Na2O8P) - High-purity pharmaceutical-grade
- Clear
- Chemically Pure
- API Standards
- Above 98%
- Above 80%
- 99-100%
- 99.99%
- 99.99
- 99.96%
- 99.95%
- 99.93%
- 99.91%
- 99.90%
- 99.9% min
- >99.9%
- 99.9%
- 99.9 min
- 99.9
- 99.87%
- 99.86%
- 99.85%
- 99.83%
- 99.82%
- 99.80%
- 99.75%
- 99.73%
- 99.70%
- 99.69%
- 99.67%
- 99.63%
- 99.62%
- 99.60%
- 99.59%
- 99.57%
- 99.55%
- 99.53%
- 99.52%
- 99.51%
- 99.50%
- 99.5%+
- 99.5% min
- ≥ 99.5%
- 99.5%
- 99.47%
- 99.45%
- 99.40%
- 99.36%
- 99.31%
- 99.29%
- 99.27%
- 99.26%
- 99.25%
- 99.23%
- 99.21%
- 99.20%
- 99.11%
- 99.05%
- 99.02%
- 99.00%
- 99%+
- 99% TO 101%
- 99% Pure
- 99% Minimum
- 99% Min
- 99% ABOVE
- 99% (By G.C)
- 99%
- >99%
- 99 %
- 99 - 101%
- 98+
- 98.93%
- 98.90%
- 98.80%
- 98.76%
- 98.70%
- 98.68%
- 98.64%
- 98.60%
- 98.57%
- 98.54%
- 98.50%
- 98.5%
- 98.42%
- 98.35%
- 98.33%
- 98.30%
- 98.23%
- 98.20%
- 98.15%
- 98.06%
- 98.04%
- 98.00%
- >98.0%
- 98%+
- 98% on dried substance
- 98% min
- 98% +
- 98%
- >98%
- > 98%
- 98 %
- 98
- 97-99%
- 97.98%
- 97.93%
- 97.90%
- 97.75%
- 97.53%
- 97.50%
- > 97.5 %
- 97.40%
- 97.39%
- 97.34%
- 97.00%
- 97%
- 97 %
- 96-99%
- 96.80%
- 96.69%
- 96.48%
- 96.31%
- 96.30%
- 96.20%
- 96.13%
- 96.03%
- 96.00%
- 96% - 104%
- 96%
- 95-99.99 %
- 95-99%
- 95-98%
- 95.88%
- 95.80%
- 95.69%
- 95.20%
- 95.10%
- 95.00%
- >95.0%(T)
- 95%-98%
- 95%+
- 95% & 97%
- 95%
- >95%
- 95 %
- 94.88%
- 94.50%
- 94.07%
- 93.21%
- 93.20%
- 93.00%
- 92.80%
- 91.87%
- 90-95%
- 90.74%
- 90% min
- 90% / 98%
- >90%
- 90 % Above
- 89%
- 86.74%
- 86%
- 85.4%
- 85%
- 80%
- 75% Min
- 70% / 80%
- 70%
- 7%,9% & 11%
- 65%
- 60-62
- 600
- 60%
- 57% Min
- 52
- 50%
- 50 %
- 5%
- 48%
- 40%
- 2604-39-9
- 25%
- 226.19
- 20.5 - 22.5%
- 20%
- 2.0M
- 160%
- 15.5% NITROGEN
- 100.00%
- 100%
- 10 %
- 1.0M/3.0M/ 3.2M
- 1.0M/2.0M
- 1.0M/0.5M
- 1.0M
- 0.5M
- 0.50M
Package
- 0KG
- 0MG TO GRAM
- 25mg
- 50mg
- 100mg
- 250mg
- 500mg
- 1gm
- 1g
- 25gm
- 50gm
- 50g
- 100gm
- 100ml
- 500ml
- 11Between 1 gm to 1 MT (As per availability)
- 200gm
- 250gm
- 500gm
- 1L
- 1and gm
- 50 gms
- 2.5501e+00925 MG 50 MG 100 MG 250 MG EXTRA
- 1kg
- 5kg
- 10kg
- 25kg
- 100kg
- 500kg
- 1000kg
- 1MT
- 27TON
- 40and kg
- 100 gms
- 500gms
- 250250 mg.
-
2-(1H-indazol-5-yl)propanoic acid
586971-28-0
-
1-(5-(2-fluorophenyl)-1H-pyrrol-3-yl)-N-methylmethanamine
1610043-62-3
-
IRBESARTAN RELATED COMPOUND A (25 MG) (1-PENTANOYLAMINO-CYCLOPENTANECARBOXYLIC ACID [2'-(1H-TETRAZOL-5-YL)-BIPHENYL-4-YLMETHYL]-AMIDE)
748812-53-5
-
Vonoprazan Fumarate impurity
1885094-62-1
-
N-(4-fluoro-2-Methoxy-5-nitrophenyl)-4-(1-Methylindol-3-yl)pyriMidin-2-aMine
1421372-94-2
-
1H-Pyrrole-3-methanamine, N-ethyl-5-(2-fluorophenyl)-1-(3-pyridinylsulfonyl)-
2247546-53-6
-
AZD-9291
1421373-65-0
-
3-[[[2-[[(4-Cyanophenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]pyridin-2-ylamino]propionic acid ethyl ester
211915-84-3
-
Ethanone,1-(5-broMo-1H-indazol-3-yl)-
886363-74-2
-
BrimonidineNitroso Impurity
2-(1H-Indazol-5-yl)propanoic acid 586971-28-0
1-(5-(2-FLUOROPHENYL)-1H-PYRROL-3-YL)-N- METHYLMETHANAMINE 1610043-62-3
N-(4-fluoro-2-methoxy-5-nitrophenyl)-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-amine 1421372-94-2
1-(5-Bromo-1H-indazol-3-yl)ethan-1-one 886363-74-2
Calcium lactate pentahydrate 63690-56-2
Coumarin 91-64-5
Diethyl phthalate 84-66-2